Novocure.com
TTFields
Tumor Treating Fields (TTFields) are electric fields that disrupt cancer cell division. TTFields are delivered to the region of the cancer using a lightweight, battery-operated medical device. Novocure is the sponsor of several clinical studies investigating TTFields treatment for different types of cancer.
Using TTFields
TTFields are delivered to the region of the tumor using a lightweight, portable medical device. The device applies TTFields non-invasively and gives patients the option to maintain their lifestyle while receiving TTFields treatment.
Novocure
Novocure is developing TTFields for different cancer diseases. Novocure maintains this website in order to assist patients, their family members, and caregivers in accessing clinical study sites for potential participation in ongoing trials. Patients should always consult with their treating physician about their treatment options.
overview
Novocure® is developing TTFields for different cancer diseases. This website is designed to assist patients, their family members, and caregivers in accessing clinical study sites for potential participation in ongoing studies.
TTFields are electric fields that disrupt cancer cell division. TTFields are delivered to the region of the cancer using a lightweight, battery-operated medical device. The device applies TTFields non-invasively, and gives patients the option to maintain their lifestyle while receiving TTFields treatment.
The use of TTFields has been approved by the FDA via the Premarket Approval Pathway for the treatment of GBM, together with temozolomide. TTFields therapy has obtained a CE mark in Europe, and is approved in Japan for the same indication. TTFields are experimental for all indications mentioned in these clinical studies and has not been approved for their treatment.
clinical trials
METIS
Brain metastasis
The METIS study is intended for patients diagnosed with brain metastases from non-small-cell lung cancer.
learn more
LUNAR
Lung cancer
The LUNAR study is intended for patients diagnosed with advanced non-small cell lung cancer (NSCLC).
learn more
ENGOT-ov50 / INNOVATE-3
Ovarian cancer
The ENGOT-0v50/INNOVATE-3 study is intended for patients diagnosed with platinum resistant, recurrent ovarian cancer.
learn more
TRIDENT
Glioblastoma
The TRIDENT study is intended for patients recently diagnosed with glioblastoma multiforme (GBM).
learn more
ZL-8301-001
Gastric cancer
The ZL-8301-001 study is intended for patients diagnosed with gastric cancer (Gastroesophageal Junction (GEJ) Adenocarcinoma, or Gastric (GC) Adenocarcinoma) that cannot be treated with surgery.
learn more
PANOVA-3
Pancreatic cancer
The PANOVA-3 study is intended for patients with newly-diagnosed pancreatic cancer that cannot be treated with surgery.
learn more
EF-33
Glioblastoma
The EF-33 study is intended for patients recently diagnosed with recurrent glioblastoma.
learn more
KEYNOTE B36
Lung cancer
The KEYNOTE B36 study is intended for patients who have been diagnosed with, but have not yet been treated for, advanced or metastatic intrathoracic non-small cell lung cancer (NSCLC).
learn more
find a trial
Enter your details below to help us find a trial match for you.